ArticleScientific reports2019
Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 93 citations in OpenAlex.
- Recent advances in fluorescent probes for guided surgery of head and neck carcinomas.RSC advances · 2026Review
- EGFR-Targeted and MMP-Activated Membranolytic Peptides Kill Cancer Cells Specifically In Vitro and Reduce Tumor Growth In Vivo.Molecular pharmaceutics · 2026Article
- Design and Synthesis of Peptide-Tagged Cubosome Nanocarriers for the Targeted Delivery of Paclitaxel in EGFR Overexpressing Breast Cancer.ACS biomaterials science & engineering · 2026Article
- An MIEN1-based hexamer peptide (LA3IK) inhibits EGF-driven oncogenic signaling in prostate cancer by disrupting EGFR-ERBB2 heterodimerization.Scientific reports · 2026Article
- DNA-programmed bispecific peptide assemblies for delivering cytotoxic payload to cells expressing EGFR and MET receptors.RSC chemical biology · 2026Article
- Harnessing albumin's natural tumor-targeting properties: nanoplatform strategies for triple-negative breast cancer therapy.Discover nano · 2026Review
- Amphiphilic Lipid-Single-Stranded DNA Conjugate-Mediated Cell Surface Engineering for Programmable Intercellular Tethering and Immune Synapse Formation.Biomaterials research · 2026Article
- EGFR-Targeted Photodynamic Treatment of Triple Negative Breast Cancer Cell Lines Using Porphyrin-Peptide Conjugates: Synthesis and Mechanistic Insight.Molecules (Basel, Switzerland) · 2025Article
- Review
- Highly Adaptable Dendrimer Gel Nanoparticles with Dual Targeting of uPAR and Ribonucleotide Reductase R2 for Better Retention and Improved Therapeutic Outcomes in Triple-Negative Breast Cancer.ACS applied materials & interfaces · 2025Article
- A Conjugate of an EGFR-Binding Peptide and Doxorubicin Shows Selective Toxicity to Triple-Negative Breast Cancer Cells.ACS medicinal chemistry letters · 2025Article
- Multi-Target Inhibitor CUDC-101 Impairs DNA Damage Repair and Enhances Radiation Response in Triple-Negative Breast Cell Line.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Modulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition.Archives of pharmacal research · 2024Article
- Gemcitabine-Lipid Conjugate and ONC201 Combination Therapy Effectively Treats Orthotopic Pancreatic Tumor-Bearing Mice.ACS applied materials & interfaces · 2024Article
- Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.International journal of nanomedicine · 2024Article
- Design of siRNA Bioconjugates for Efficient Control of Cancer-Associated Membrane Receptors.ACS omega · 2023Article
- 5,10,15,20-Tetrakis(pentafluorophenyl)porphyrin as a Functional Platform for Peptide Stapling and Multicyclisation.Chemistry (Weinheim an der Bergstrasse, Germany) · 2023Article
- Fabrication of a Dual-Targeted Liposome-Coated Mesoporous Silica Core-Shell Nanoassembly for Targeted Cancer Therapy.ACS omega · 2023Article
- Design of Highly Fluorinated Peptides for Cell-basedBioconjugate chemistry · 2023Article
- Knockdown of PTK7 Reduces the Oncogenic Potential of Breast Cancer Cells by Impeding Receptor Tyrosine Kinase Signaling.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The efficacy of chemotherapy for cancer treatment can be increased by targeted drug delivery to the cancer cells. This is particularly important for triple negative breast cancer (TNBC) for which chemotherapy is a major form of treatment. Here we designed and screened a library of 30 peptides starting with a previously reported epidermal growth factor receptor (EGFR) targeting peptide GE11 (YHWYGYTPQNVI). A direct peptide array-whole cell binding assay, where the peptides are conjugated to a cellulose membrane, was used to identify four peptides with enhanced binding to TNBC cells. Next, the four peptides were synthesized as FITC-labelled soluble peptides to study their direct uptake by TNBC cells using flow cytometry. The results showed that peptide analogue 22 had several fold higher uptake by the TNBC cells compared to the lead peptide GE11. The specific uptake of the peptide analogue 22 was confirmed by competition experiment using pure EGF protein. Further, peptide 22 showed dose dependent uptake by the TNBC MDA-MB-231 cells (10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.